IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.9800
-0.0400 (-3.92%)
At close: May 16, 2025, 4:00 PM
0.9800
0.00 (0.00%)
After-hours: May 16, 2025, 7:56 PM EDT
IO Biotech Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for IO Biotech stock ranges from a low of $6.00 to a high of $12. The average analyst price target of $9.33 forecasts a 852.04% increase in the stock price over the next year.
Price Target: $9.33 (+852.04%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 1, 2025.
Analyst Ratings
The average analyst rating for IO Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,124.49% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,124.49% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,124.49% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,124.49% | Nov 6, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +512.24% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
n/a
from 266.45M
Revenue Next Year
n/a
EPS This Year
-1.42
from -1.45
EPS Next Year
-1.15
from -1.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 48.8M | 137.5M | ||
| Avg | n/a | 17.1M | 77.2M | ||
| Low | n/a | n/a | 23.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 703.9% | ||
| Avg | - | - | 351.3% | ||
| Low | - | - | 39.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.23 | -0.92 | -0.70 | ||
| Avg | -1.42 | -1.15 | -0.75 | ||
| Low | -1.47 | -1.48 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.